Lee Schalop, MD

Dr. Schalop co-founded Oncoceutics in 2009 and served in progressively senior roles, including Chief Business Officer (2009-2016), Chief Operating Officer (2016-2020), and Chief Executive Officer (2020-2021). Under his leadership, Oncoceutics advanced its targeted therapies through clinical development, ultimately leading to the company’s successful acquisition by Chimerix Inc. (NASDAQ: CMRX) for $450 million in January 2021. Following the acquisition, Dr. Schalop served as a Board Observer at Chimerix until its subsequent acquisition by Jazz Pharmaceuticals for $935 million in April 2025.

Prior to his biotech career, Dr. Schalop spent 19 years in the financial industry at major Wall Street firms including Morgan Stanley, J.P. Morgan, Credit Suisse, and Banc of America Securities, serving as both an investment banker (1985-1993) and research analyst (1993-2004). This unique combination of financial expertise and medical training has enabled him to successfully bridge the gap between scientific innovation and commercial viability.

Dr. Schalop earned his Doctor of Medicine degree from Albert Einstein College of Medicine in 2008 and he is a summa cum laude graduate of the University of Pennsylvania where he earned dual degrees from the University’s Wharton School and College of Arts and Sciences. He currently serves on the Supervisory Board of TME Pharma N.V. (Euronext Growth Paris: ALTME) and he sits on the advisory board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania.

‍